MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jphs.2024.06.005

Медицинская библиотека · Journal of pharmacological sciences · 2024

Contribution of MLKL to the development of doxorubicin-induced cardiomyopathy and its amelioration by rapamycin.

Shimizu Masaki, Ohwada Wataru, Yano Toshiyuki, Kouzu Hidemichi, Sato Tatsuya, Ogawa Toshifumi, Osanami Arata, Toda Yuki, Nagahama Hiroshi, Tanno Masaya, Miura Tetsuji, Kuno Atsushi, Furuhashi Masato

СтатьяПеревод пока не подготовлен

Аннотация

Necroptosis, necrosis characterized by RIPK3-MLKL activation, has been proposed as a mechanism of doxorubicin (DOX)-induced cardiomyopathy. We showed that rapamycin, an mTORC1 inhibitor, attenuates cardiomyocyte necroptosis. Here we examined role of MLKL in DOX-induced myocardial damage and protective effects of rapamycin. Cardiomyopathy was induced in mice by intraperitoneal injections of DOX (10 mg/kg, every other day) and followed for 7 days. DOX-treated mice showed a significant decline in LVEF assessed by cardiac MRI (45.5 ± 5.1% vs. 65.4 ± 4.2%), reduction in overall survival rates, and increases in myocardial RIPK3 and MLKL expression compared with those in vehicle-treated mice, and those changes were prevented by administration of rapamycin (0.25 mg/kg) before DOX injection. In immunohistochemical analyses, p-MLKL signals were detected in the cardiomyocytes of DOX-treated mice, and the signals were reduced by rapamycin. Mlkl+/- and Mlkl-/- mice were similarly resistant to DOX-induced cardiac dysfunction, indicating that a modest reduction in MLKL level is sufficient to prevent the development of DOX-induced cardiomyopathy. However, evidence of cardiomyocyte necrosis assessed by C9 immunostaining, presence of replacement fibrosis, and electron microscopic analyses was negligible in the myocardium of DOX-treated mice. Thus, MLKL-mediated signaling contributes to DOX-induced cardiac dysfunction primarily by a necrosis-independent mechanism, which is inhibitable by rapamycin.

Для цитирования: Shimizu Masaki, Ohwada Wataru, Yano Toshiyuki, Kouzu Hidemichi, Sato Tatsuya, Ogawa Toshifumi, Osanami Arata, Toda Yuki, Nagahama Hiroshi, Tanno Masaya, Miura Tetsuji, Kuno Atsushi, Furuhashi Masato. Contribution of MLKL to the development of doxorubicin-induced cardiomyopathy and its amelioration by rapamycin.. Journal of pharmacological sciences. 2024. DOI: 10.1016/j.jphs.2024.06.005.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.